课题基金 / 基金详情

High Throughput screen to identify "first of their kind" activators of ADCY10

High Throughput screen to identify "first of their kind" activators of ADCY10
高通量筛选,鉴定 ADCY10 的“同类首个”激活剂
批准号:
10066301
负责人:
JOCHEN BUCK
金额:
$56.94万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-02-01 至 2022-11-30

项目摘要

项目成果

JOCHEN BUCK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Aberrant accumulation of protein aggregates is a common feature of age-related neurodegenerative diseases, including Alzheimer's disease. Cells clear aggregated material via autophagy. Lysosomes, the acidic organelles where proteins and unused cellular components are degraded and recycled, are the terminal compartment of autophagy. Long-lived, post-mitotic cells such as neurons are dependent upon continuous lysosomal turnover of cellular materials delivered by autophagy. With aging, lysosomes become less acidic, and their proteolytic activity decreases. In a cellular model of Alzheimer's disease, re-acidification of lysosomal pH increases autophagic flux and rescues cell function. We discovered a signaling cascade which regulates lysosomal acidification. Soluble adenylyl cyclase (sAC) is a source of the ubiquitous second messenger cAMP which is molecularly, structurally, biochemically, and functionally distinct from the family of plasma membrane-bound, hormone-regulated transmembrane forms of adenylyl cyclase. We showed sAC-generated cAMP promotes lysosomal acidification, and in the absence of sAC activity, autophagic flux is slowed. There are no pharmacological activators of sAC. We previously used high throughput screening to identify the most widely used pharmacological inhibitors specific sAC. We now propose to use high throughput screening and our battery of in vitro and cellular sAC assays to identify and characterize “first-of-their kind” small molecule activators selective for sAC usable in cellular systems. We hypothesize that sAC activators will facilitate lysosomal acidification and increase degradation of accumulated protein aggregates in cellular models of neurodegenerative disorders. These studies have the potential to supply proof- of-principle for a therapeutic strategy to treat neurodegenerative disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Assessing inhibitor efficacy in vivo and developing a biomarker for use during early phase clinical trials
On-demand nonhormonal male contraception via ADCY10 inhibition
Development of new ADCY10 inhibitors
Optimization of lead candidates for an on-demand male contraceptive
海外基金